Background: Few studies have evaluated the effects and precise molecular mechanism of mycophenolate mofetil (MMF) in the treatment of human cutaneous lupus erythematosus (CLE). Our findings shed light on the therapeutic effects of MMF in a UVB-induced NZB Â NZW (NZBW) F1 CLE mouse model. Methods: Continuous MMF treatment (60 mg/kg/day) was administered up to Day 50 from the beginning of UVB induction (Day 0; 20 weeks old), as the pathologic features of CLE are present after 50 days. The therapeutic effects of MMF treatment in NZBW lupus mice were examined by comparing histopathological changes, lupus band test (deposition of immune complexes at the dermaleepidermal junction) and colocalization of autoantibodies with a dermal autoantigen Dsg3, and by evaluating the associations of local matrix metalloprotease activities. Results: MMF improved survival in the NZBW lupus mice from 35.7% to 81.8%. The proteinuria, blood urea nitrogen, and interleukin 6 levels were significantly reduced after MMF treatment. The dermal lymphocytic infiltration, deposition of immune complexes at the dermaleepidermal junction, colocalized autoantibodies with Dsg3, and epidermal matrix metalloprotease activity were also attenuated in MMF-treated NZBW F1 mice.
Introduction
Lupus erythematosus (LE) includes a disease group that may involve one or many organ systems. Skin involvement is a major feature of LE in 70e85% of patients with systemic LE. Cutaneous LE (CLE) includes subacute CLE, LE tumidus and discoid LE. Of these, the most photosensitive are subacute CLE and LE tumidus. The anti-Ro/SSA antibody is strongly correlated with subacute CLE but rarely present in discoid LE or LE tumidus.
1,2 Ultraviolet (UV) light (UVA, UVB), and visible light can provoke lesions in all photosensitive forms of CLE. 3e5 These dermatological manifestations are welldescribed and are typically characterized by extensive deposition of immunoglobulin G (IgG), IgM, and IgA, as well as complements C3 and C1q. Dermal MMP-2 and MMP-9 with gelatinase activity can degrade extracellular matrix, making them accessible for the deposition of immune complexes and promoting progression of the disease in the skin of lupusprone mice. 6 Mycophenolate mofetil (MMF), an inhibitor of inosine monophosphate dehydrogenase (IMPDH), acts as a selective and potent immunosuppressive agent and affects the gonadal organs to a lesser extent than other immunosuppressants. It is a potent inhibitor of the type II isoform of IMPDH, which is expressed in activated lymphocytes. Its inhibitory effect on the type II form of IMPDH is five-fold that for the type I isoform, which is expressed in most cell types. 7, 8 However, there are very few data on MMF treatment of skin manifestations in LE. Skin diseases such as bullous pemphigoid, pemphigus, psoriasis, and atopic dermatitis have been shown to improve significantly with MMF treatment. 9, 10 MMF also seems to be a successful approach for the treatment of therapy-resistant skin lesions of subacute CLE. 11 However, the role of MMF in CLE therapy is yet to be clearly established.
Human SLE and its murine models, MRL/lpr or NZB Â NZW (NZBW) mice, are well known to be characterized by a wide range of symptoms, such as glomerulonephritis, dermatitis, arthritis, and Ig deposition at the dermaleepidermal junction (DEJ) of the skin. 12 Desmoglein 3 (Dsg3), a major component of epidermal desmosomes, was identified as a skin-specific autoantigen. The anti-Dsg3 IgA was found to be most correlated with skin disease aggravation. 13 UVB exposure accelerates the development of lesions and immune deposits, but does not accelerate systemic disease. Skin disease in murine lupus requires T cells and, to a lesser extent, B cells but is independent of antibody production. Long-term exposure to low-dose UVB irradiation accelerated the development of skin lesions and enhanced the intensity of the positive skin lupus band. The contents of anti-DNA antibodies in sera, the incidence of positive findings in skin lupus band test (LBT), and the extent of glomerulonephritis were not influenced by the UVB irradiation. 14, 15 Although MMF has been shown to have a beneficial effect in preventing disease development in mice, the precise cellular and molecular mechanism of its action is not completely known, especially with regard to its role in the development of skin inflammation. Herein, in order to gain insight into the therapeutic effects of MMF, UVB-induced NZBW F1 mice were treated with MMF and changes in cutaneous manifestations, histopathology, immunopathologic features, and laboratory abnormalities were assessed.
Methods

Animals and treatments
The experiments were conducted in accordance with the U.S. National Institute of Health Guide for the Care and Use of Laboratory Animals and the Animal Research Guidelines of Taichung Veterans General Hospital (the Institutional Animal Care and Use Committee Approval No: La-99738). Female 11-week-old NZBW F1 mice were purchased from the laboratory animal center of National Taiwan University College of Medicine and were assessed when they were aged 20 weeks, when proteinuria and cutaneous lesion were present. Proteinuria was assessed by determination of urine albumin using reagent striped Albustix (Bayer, Spain) and was scored on a 0e4 scale: 0 indicates the absence of or trace levels of proteinuria; 1 indicates proteinuria values of 0.30e1.00 g/L; 2 indicates values of 1.0e3.0 g/L; 3 indicates values 3.0e10.0 g/ L; and 4 indicates values >10.0 g/L. After the mice were sacrificed at Day 190, the serum was collected for examination of blood urea nitrogen (BUN) and interleukin 6 (IL-6) levels.
Ultraviolet light irradiation on the skin
A sun lamp was used to emit mid-wave UV light ranging from 290 nm to 315 nm (mainly UVB) with a peak at 305 nm, and the energy output of a bank of three tubes was 2.4 mW/ cm 2 at a distance of 15 cm measured using a UVR-305/365 UV-Radiometer (Toshiba Medical Supply, Tokyo, Japan). 15 The two experimental groups (with or without MMF treatment) comprised 20-week-old NZBW F1 mice. The dorsal skin of the mice was shaved twice a week, and an irradiation dose of 500 mJ/cm 2 was administered every other day in a photoirradiation cage, and each mouse received 28 doses in total.
MMF treatment of NZBW F1 mice
The beginning of UVB induction was Day 0. When cutaneous lesions were present in NZBW F1 mice at age 6 months (Day 50), MMF (purchased from Roche Pharmaceuticals, Inc., Basel, Switzerland) was provided as a daily gavage at a dose of 60 mg/kg. MMF was started at Day 50 and administered until the experiment ended on Day 190.
Dermal morphological examination and histochemical staining
The dorsal skin of the mice was fixed in neutralized 10% formaldehyde solution. A routine pathologic examination of the skin was performed and examined by hematoxylin and eosin (H&E) staining. Optimal cutting temperature compound-embedded skin was stored at À70 C until cryostat sectioning at 5 mm thickness for immunofluorescence staining and in situ zymography. The severity of skin inflammation was examined by the sum of the involved skin area score and the scorings for three items: inflammatory cell infiltration, edema and scaling/hyperkeratosis in H&E staining. 16, 17 The degree of each item was assessed as follows: 0 ¼ no symptoms; 1 ¼ light; 2 ¼ mild; 3 ¼ severe. 17 The infiltrated inflammatory cells were further compared by CD4 and CD8 cell counting on an immunofluorescence graph. 17 
Identification of immunodeposition in skin
The LBT was performed on the dorsal skin of the examined mice.
14 Briefly, 5 mm-thick (approximately) frozen sections mounted on glass slides were dried and washed in phosphatebuffered saline (PBS). The skin sections were reacted with Texas red conjugated horse anti-mouse IgG (Vector) and fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse IgM (Abcam, Cambridge, UK), and observed under a laser confocal microscope (FV1000-D; Olympus, Tokyo, Japan).
Immunofluorescence staining for Dsg3 and deposition of immune complexesdlaser confocal microscopy imagery
To detect Dsg3 as a tissue-specific autoantigen in NZBW F1 mice, serial frozen sections of dermal tissues from these mice were assessed by a specific goat anti-Dsg3 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and FITC-conjugated horse anti-mouse IgG monoclonal antibody for immunofluorescence double staining according to the manufacturer's instructions. Nonspecific Ig binding sites were blocked with normal bovine serum for 30 minutes at room temperature, and then with goat anti-Dsg 3 polyclonal antibody with PBS-Triton 100 containing 5% nonfat milk. After incubation at 4 C overnight, the dermal sections were washed with PBS and incubated with rhodamine-conjugated donkey anti-goat IgG for 1 hour at room temperature. Then, FITC-conjugated horse anti-mouse IgG antibody was incubated for 1 hour at room temperature to detect immunocomplex. After washing with PBS and mounting, the fluorescence was imaged using a laser confocal microscope (FV1000-D).
In situ zymography
To detect the loci of extracellular matrix proteolytic activity (MMPs activity) within frozen skin sections of onset and MMFtreated animals, an in situ zymography approach was employed. 18, 19 Briefly, 8 mm skin sections were washed in PBS and incubated for 2 hours in DQ-labeled gelatin (Invitrogen, Carlsbad, CA, USA) substrate solution (20 mg/mL DQ-gelatin, 50 mM Tris pH 6.8, 50 mM NaCl, 20 mM CaCl 2 ) at 37 C in the dark. Substrate solution was washed off, slides were incubated in 4% formaldehyde for 10 minutes, washed with PBS, mounted with Dapi-Fluoromount-G (SouthernBiotech, Birmingham, AL, USA), and photographed with identical exposure settings using a laser confocal microscope (FV1000-D).
Gel zymography
The frozen skin tissue was homogenized in Tris buffer (50 mM Tris-HCl, pH 7.5, 150 mmol/l NaCl) and then centrifuged, after which the supernatant was collected. The protein content of supernatants was determined by preparing BSA solution as the standard curve. A 20-mg sample of protein from each tissue sample was run on 8.0% SDS-PAGE containing gelatin (1.0 mg/mL) without previous heating or reduction. After electrophoresis, gelatin-lytic bands were identified by staining with Coomassie Brilliant Blue and the images were analyzed with a 1-D Gel-Pro analyzer.
Statistical analysis
All values are expressed as mean AE standard deviation. Parametric continuous data between different groups were analyzed by KruskaleWallis nonparametric test. All statistical analyses were conducted using the SPSS version 10.1 (SPSS Inc., Chicago, IL, USA). A p value <0.05 (2-tailed) was considered statistically significant. 
Results
Clinical findings and survival rates
Proteinuria was raised from 1 to >2 in NZBW F1 mice at age 17 weeks. UVB induction was initiated at age 20 weeks (Day 0) until the proteinuria was above 50%, and in the NZBW F1 mice, the level of proteinuria was 2 plus. MMF therapy was added at Day 50 when mild melanosis or dermatitis was observed. After UVB induction (Day 105), the first deaths among the NZBW F1 mice were noted (Fig. 1A) . Following MMF treatment, the survival rate of MMF group was significantly higher on Day 128 and beyond ( p < 0.05). Until the end of the experiment (Day 190), the survival rate of UVB-induced NZBW F1 mice was significantly low (35.7%, 5/14) as compared with that in mice that received MMF treatment (81.8%, 9/11; Fig. 1A , p < 0.05). In UVB-induced NZBW F1 mice, 78.6% (11/14) had a proteinuria level >2. The proteinuria was significantly improved in MMF-treated NZBW F1 mice (Fig. 1B, p < 0.05) . After sacrifice and collecting serum for renal function assay (Day 190), the MMF group showed a significant decrease in the serum BUN level (Fig. 1C, p < 0. 05) but no difference in creatinine level. The concentrations of serum IL-6 in the NZBW and MMF groups were 10.23 AE 4.92 pg/mL (n ¼ 11) and 2.84 AE 0.87 pg/mL (n ¼ 14), respectively (Fig. 1D) . After MMF treatment, the serum IL-6 level was significantly reduced (Fig. 1D , p < 0.001).
Pathologic findings after MMF treatment
Subcutaneous edema and moderate infiltration of inflammatory cells were noted in NZBW lupus mice ( Fig. 2A and B) . The infiltrated cells were lymphocytes (Fig. 2C) . Mild epithelial parakeratosis and homogenous substance deposition in the derma were also present in NZBW lupus mice (Fig. 2B) . After MMF treatment, the epithelial parakeratosis and homogeneous substance deposition in the dermis were attenuated ( Fig. 2D and E) . The scoring of the skin inflammation severity revealed that MMF treatment significantly decreased the severity of skin lesions (Fig. 2G, p < 0.05) . The lymphocyte results revealed that the infiltration of CD8 T cells was also markedly attenuated in MMF-treated NZBW F1 mice (Fig. 2F, green) . However, the number of CD4 T cells was not significantly affected in this local distribution (Fig. 2F, red) . The graph counting results in Fig. 2G show that infiltrated CD8 T cells but not CD4 T cells were attenuated ( p < 0.05).
Deposition of immune complexes in UVB-induced NZBW F1 mice
Deposition of immune complexes was identified using immunofluorescence staining pattern with the antibody to IgG and IgM showing evidence for immune complexes at the DEJ. Both IgG and IgM deposition (deposition of immune complexes) were conspicuous at the DEJ and dermis in UVBinduced NZBW lupus mice (Fig. 3A) . However, this pattern appeared to be reduced in the skin of UVB-induced NZBW F1 mice with MMF treatment (Fig. 3B) . Regarding the quantification of lupus band (deposition of immune complexes at the DEJ), there was a reduced tendency for the deposition of immune complexes in the MMF-treated group (Fig. 3C ). The IgG intensity was significantly attenuated in the MMF group (Fig. 3C , p < 0.05), but IgM intensity was unchanged (Fig. 3C, p > 0.05) .
Deposition of immune complexes colocalized with Dsg3
The immune complexes at the DEJ were represented by anti-IgG staining (green color) in NZBW lupus mice (Fig. 4A) and MMF-treated mice (Fig. 4B) . After merging the Dsg3 protein staining (Fig. 4A and B, red color) , the colocalized image of IgG and Dsg3 showed significant staining (yellow color) at the DEJ in NZBW lupus mice (Fig. 4A, merge) , whereas there was negligible staining in the MMF treatment group (Fig. 4B, merge) . This pattern was more clearly apparent in the close-up images (Fig. 4C and D) . The rate of IgG colocalization with Dsg3 was significantly attenuated after MMF treatment (Fig. 4E , p < 0.001).
In situ zymography
Using a fluorescently labeled gelatin substrate, frozen skin sections were assayed for total gelatinase (MMPs) activity. The major gelatinase activity occurred at the epithelial layer (Fig. 5A) . NZBW F1 skin showed a high-level of gelatinase activity with a wide, thick band (Fig. 5A, top) , and a similar signal band was also detected in the skin section of MMFtreated mice, but gelatinase activity was attenuated (Fig. 5A,  bottom) . After quantification of gelatinase activity at the epithelium, MMP intensity was significantly attenuated at the epidermis and DEJ in the MMF group ( p < 0.001; Fig. 5B ).
Gelatin zymography
Gelatinolytic activities of the skin samples were detected by zymography (Fig. 5C ). The gelatin-lytic bands at 92 (proMMP-9), 72 (proMMP-2), and 62 (MMP-2) kDa are presented in Fig. 5C and their internal control protein (atubulin) was also analyzed by Western blot (Fig. 5C) . Following MMF treatment, proMMP-2 and MMP-2 activity in the skin was reduced and the intensity was significantly attenuated in proMMP-2 (Fig. 5D , p < 0.05).
Discussion
CLE and its various clinical subtypes cause dermal inflammation culminating in keratinocyte damage at the DEJ. 20 During the initiation phase, an autoimmune aberrant response induces tissue injury. Environmental factors are necessary to trigger the immune system, and these include UV light. A systematic review of the recent literature on CLE showed that mouse models, such as the MRL/lpr, NZBW, and BSXB mouse strains, can be used to study the mechanisms underlying the disease as well as therapeutic options. In NOD mice, delayed clearance of apoptotic debris and high autoantibody production were found following repeated UV irradiation. 21 Recently, the mechanisms of UVB irradiation in autoinflammatory skin disease have been extensively revealed. IL-6 stimulates B cell differentiation, directly inducing the IgG anti-DNA antibodies secretion, and promotes the differentiation of cytotoxic T cells. SLE patients release IL-6 in response to UVA or UVB irradiation possibly contributing to the flareup of skin lesions. 22 In this study, a raised IL-6 level was also found in NZBW mice, and MMF treatment significantly reduced the IL-6 level (Fig. 1D, p < 0.001) . Other cytokines, colony-stimulating factor 1, IFN-related proteins and high mobility group box protein 1 were also correlated with the disease progression in the sera of MRL/lpr mice or humans. 23e25 The incidence of IgG deposition at the DEJ of MRL/lpr mice increases with age and reaches more than 80% after age 14, 26 The skin of NZBW F1 mice were found to have Ig deposition at the DEJ, indicating that skin-specific autoantigen or/and autoantibodies play a role in exacerbating or amplifying the manifestation of skin disease. 13 Therefore, we performed this study when mice had reached age 20 weeks and there was evidence of systemic lupus onset, such as the presence of proteinuria. Skin membrane structures are able to bind chromatineIgG complexes, and upregulated expression of structures in skin membranes may increase the binding capacity of such immune complexes. Reduced expression would eventually be beneficial for the organs in which deposition occurs. 6 In this study, we established a UVB-induced NZBW lupus mouse model and identified cutaneous lesions, including skin inflammation with CD4 and CD8 lymphocytic infiltration (Fig. 2AeC) . MMF treatment was significantly beneficial for decreasing IgG immune complexes deposition (Fig. 3) . The intensity of IgG immune complex deposition, considered a chronic immune globulin, at the DEJ was significantly attenuated in the MMF group (Fig. 3C ,
The use of typical treatments, such as steroids with systemic treatment, usually provides additional benefit. Nevertheless, many patients suffer from treatment side effects and cutaneous lesions that are resistant to therapy. There is a need therefore for alternative therapies. MMF is a selective and potent immunosuppressive agent and affects the gonadal organs to a far lesser degree than other immunosuppressants.
Dsg3 was identified as an autoantigen in a human skin autoimmune disease, which was first discovered in bullous pemphigus vulgaris, in which Dsg3 is present microscopically in the suprabasal layer of the epidermis. Dsg3 possesses pathogenic properties and its presence results in the production of autoantibodies. Although an association has been reported in the MRL/lpr mouse model, 13 it has not been previously described in CLE patients 27 or in the NZBW mouse model. In this study, deposition of immune complexes (IgG) was observed in significant amounts and it was found that they had colocalized with the autoantigen Dsg3 at the basal layer and even between the spinous layers of the skin in NZBW lupus mice (Fig. 4A and C ), but this was not shown in NZBW lupus mice with MMF treatment (Fig. 4B and D) . This demonstrates that strong associations exist among autoantibody (IgG) deposition, Dsg3 exposure, and severity in the NZBW model. However, skin inflammation in the murine models exhibit some histological dissimilarity compared with that in models of skin lesions in human SLE. Therefore, whether or not human SLE patients develop anti-Dsg3 counterparts in these murine models requires further study.
Hedberg et al 6 revealed that upregulated intradermal MMP activity may be crucial for the deposition of immune complexes in the skin of lupus-prone mice, and showed that dermal MMP-2 and MMP-9 increase CLE disease progression. We also found a high level of local gelatinase activity in NZBW F1 skin (Fig. 5A) . MMP intensity was significantly attenuated at the epidermal and DEJ in the MMF group (Fig. 5B) . The results also showed that proMMP-2 activity was significantly reduced in the whole skin sample by gelatin zymography (Fig. 5 C and D) .
T cells have been found to be prominent within lesions of CLE. 28 Cytotoxic skin-homing CD8 þ T cells in particular are conspicuous within the scarring lesions of discoid CLE and may be sufficient to initiate lupus-like autoimmunity. 28, 29 Furthermore, T cells may act at multiple stages in lupus, including modulation of B cells to secrete autoantibodies, and regulation of the activity of effector cells, such as macrophages and NK cells. 30 MMF can induce apoptosis of activated lymphocytes, thereby eliminating cells responding to antigenic stimulation and subsequently decreasing the recruitment of lymphocytes and monocytes into sites of inflammation. 7, 8 In this study, we observed that the recruitment of CD8 lymphocytes in the subcutaneous site was significantly reduced after MMF treatment ( Fig. 2F and G) . This change may indirectly attenuate antigenic stimulation, such as autoantibody to Dsg3 (Fig. 4) . The results revealed that the LBT was indeed attenuated (Figs. 3 and 4) , and thus we speculate that the B cell function was inhibited after MMF treatment.
In conclusion, MMF was greatly beneficial in the treatment of cutaneous lupus erythematosus (CLE) in NZBW F1 mice through the inhibition of proliferative responses of T lymphocytes as well as B lymphocytes, which implies that levels of antibodies were dramatically diminished. However, activity of MMPs was associated with the severity of CLE, so further study is needed to confirm its potential clinical value for CLE prognosis.
